Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017326
|
| MeSH Number(s) |
E05.318.760.250.500.220 N05.715.360.775.088.500.220 N06.850.520.450.250.250.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Olsson LT, Walens A, Hamilton AM, Benefield HC, Fleming JM, Carey LA, Hursting SD, Williams KP, Troester MA. Obesity and Breast Cancer Metastasis across Genomic Subtypes. Cancer Epidemiol Biomarkers Prev. 2022 10 04; 31(10):1944-1951.
-
Belyea L, Acoba JD. Internal Medicine Residents' Perception of Cancer Prognosis. J Cancer Educ. 2020 10; 35(5):983-987.
-
Arora S, Sood A, Dalela D, Tang HJ, Patel A, Keeley J, Trinh QD, Rogers CG, Menon M, Abdollah F. Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. Eur Urol. 2019 02; 75(2):352-353.
-
Wren C, Bell E, Eiland LS. Ozenoxacin: A Novel Topical Quinolone for Impetigo. Ann Pharmacother. 2018 12; 52(12):1233-1237.
-
Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
-
Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1235-47.
-
Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast. 2013 Aug; 22 Suppl 2:S57-65.
-
Francia G, Kerbel RS. Raising the bar for cancer therapy models. Nat Biotechnol. 2010 Jun; 28(6):561-2.
-
Bertino P, Carbone M, Pass H. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother. 2009 Jan; 10(1):99-107.
-
Newman PA, Duan N, Lee SJ, Rudy E, Seiden D, Kakinami L, Cunningham W. Willingness to participate in HIV vaccine trials: the impact of trial attributes. Prev Med. 2007 Jun; 44(6):554-7.